Home News Roundup: CardieX files 510(k) for dual blood pressure, arterial health monitor and...

Roundup: CardieX files 510(k) for dual blood pressure, arterial health monitor and more briefs

27
0



CardieX files 510(k) for dual blood pressure, arterial health monitor

Australia-listed health tech firm CardieX has filed a 510(k) premarket submission with the US Food and Drug Administration for its dual blood pressure and arterial health monitor.

Called the CONNEQT Pulse, the health monitor features CardieX’s FDA-cleared SphygmoCor technology which measures central blood pressure to obtain multiple arterial health indicators, such as arterial stiffness, pulse pressures, and key indicators of the vascular health of the brain, heart, kidneys, and other major organs.

The Pulse will be the first incorporation of SphygmoCor into a blood pressure monitor, the company said.

Moreover, the device can be integrated with the CONNEQT mobile app for consumers. It can also be connected with the CONNEQT physician portal to enable remote patient monitoring and management. 

Both the patient app and doctor portal allow the parameters captured by Pulse to be customised and prioritised, enabling personalised insights into specific health conditions.

“For example, a patient at risk for Alzheimer’s may wish to prioritise the display of central pulse pressure and arterial stiffness, whereas a patient looking to manage hypertension may wish to prioritise both central and brachial blood pressure readings,” the company explained.


4DMedical extends partnership with I-MED nationwide

Health tech company 4DMedical and radiology services provider I-MED Radiology Network have expanded their partnership nationwide.

I-MED, which runs a network of more than 250 clinics across Australia, previously entered into a commercial deal to deploy 4DMedical’s lung imaging technology in some of its clinics in Berwick, Brisbane, Wagga Wagga, Launceston and Albury. 

Those clinics have used 4DMedical’s diagnosis support and disease surveillance tool called the XV Lung Ventilation Analysis Software to diagnose diseases such as long COVID-19, asthma, COPD and silicosis.

The new three-year agreement seeks to bring the XV imaging technology to other selected i-MED clinics across the country. Multiple clinics in Sydney, Melbourne, Adelaide, and Perth were said to be prepared for launch.

“[The] expansion of our proven capability nationwide means many more people will be able to access the latest technology in respiratory imaging,” said Dr Andreas Fouras, CEO and managing director of 4DMedical.

As part of the deal, both companies also agreed to establish a Lung Centre of Excellence leveraging 4DMedical’s XV technology “to enable world-class research and development activities to advance diagnostic imaging” in Australia.


Institute of Functional Neuroscience rolls out neuroplasticity intervention software

The Institute of Functional Neuroscience in Australia has launched its neuroplasticity intervention application in partnership with the US-based life science software company MetaCell.

Called IFN Neurologic, the software is used to perform restorative neuroplasticity interventions. Neuroplasticity refers to the brain’s ability to modify, change, and adapt in response to experience.

According to a press statement, the application will help clinicians better serve patients with neurological disorders and provide treatments in the area of functional neuroscience. 

“With this new software that requires no installation and can be reached from any web browser in the world, we now have the ability to rapidly scale our diagnostic processes and reach more patients around the world at the click of a button,” said IFN Director Dr Randy Beck.

Piloted last year, IFN Neurologic is now available to clinics and patients worldwide as part of an affiliate programme, which also includes a comprehensive education programme and other required hardware and software.

Previous articleHow to Save Money on Prescription Drugs Using Coupons
Next articleSupreme Court Curbs EPA’s Authority Over Power Plant Emissions